Apellis Pharmaceuticals
APLS
APLS
243 hedge funds and large institutions have $5.19B invested in Apellis Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 96 increasing their positions, 83 reducing their positions, and 40 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
2% less funds holding
Funds holding: 249 → 243 (-6)
10% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 40
22% less capital invested
Capital invested by funds: $6.65B → $5.19B (-$1.45B)
Holders
243
Holding in Top 10
12
Calls
$81.6M
Puts
$55.8M
Top Buyers
| 1 | +$205M | |
| 2 | +$46.9M | |
| 3 | +$35.7M | |
| 4 |
OCA
Octagon Capital Advisors
New York
|
+$34M |
| 5 |
BlackRock
New York
|
+$31.9M |
Top Sellers
| 1 | -$63.7M | |
| 2 | -$62M | |
| 3 | -$57.6M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$31.1M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$29.2M |